TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year.

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Alcoa

GE Vernova LLC

Incyte

RadNet

Semtech

Vertex Pharmaceuticals

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial.

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. The Company raised its full-year revenue guidance to $300-305 million, indicating confidence in Briumvi's market performance despite competitive pressures from Ocrevus and Kesimpta.

TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Tara Bancroft - TD Cowen Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B.

TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript

TG Therapeutics (TGTX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.73 per share a year ago.

TG Therapeutics (TGTX) Lags Q3 Earnings Estimates

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts. The post TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results appeared first on Investor's Business Daily.

TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results

Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

GoDaddy

Netflix

Oracle

Two of the five top stocks to watch this week target the artificial intelligence market. The post AI Stocks Meta, Oracle Lead Five Names Near Buy Points appeared first on Investor's Business Daily.

AI Stocks Meta, Oracle Lead Five Names Near Buy Points

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S.

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's convenience profile does not look threatening and Roche believes it represents an incremental growth opportunity, primarily in treatment centers where IV infusions are not possible. Convenience should also be the third consideration for patients, after efficacy and safety, and Briumvi's position on both still looks strong.

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully eliminate initial BRIUMVI infusion NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Insmed

Viking Therapeutics

Aspen Aerogels

AST SpaceMobile

Cava Group, Inc.

Cinemark Holdings

On Holding AG

Sweetgreen

SL Green Realty

Western Alliance Bancorporation

XPO Logistics

Subscribers to  Chart of the Week  received this commentary on Sunday, September 8.

These 12 Stocks are Ripe for a Short Squeeze

argenx

Eli Lilly

Rhythm Pharmaceuticals

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 – 20, 2024, in Copenhagen, Denmark. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2024 Programme. Details of the presentations are outlined below.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Jenna Bosco - Senior Vice President of Corporate Communications Conference Call Participants Roger Song - Jefferies Matt Kaplan - Ladenburg Thalmann Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Ed White - H.C.

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

Cassava Sciences Inc

Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).

2 Biotech Stocks Making Moves Today

TG Therapeutics stock popped Tuesday after the drugmaker unexpectedly reported a second-quarter profit, thanks to significantly lower R&D.

TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%

TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.

TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates

STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty (“HCRx”), in conjunction with funds managed by Blue Owl Capital (“Blue Owl”), has entered into a $250 million term loan facility (the “Initial Term Loan”) with TG Therapeutics, Inc. (“TG”, NASDAQ: TGTX), a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In January 2023, TG launched BRIUMVI® (ublituximab-xiiy), an anti-CD20 mono.

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S.

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with less room for significant increases in the full-year guidance after a large increase in May. New patient starts should exceed 1,400 in the second quarter, and we should hear management comments on how they are preparing for the launch of subcutaneous Ocrevus in Q4.

TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance

Among the best stocks to watch, biotech leader TG Therapeutics is clearing a key resistance area on the stock market today.

News for TG Therapeutics Stock (TGTX)